Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older, With an Extension Period of up to 60 Months

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older, With an Extension Period of up to 60 Months

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiomolibdate choline (Primary) ; Penicillamine; Trientine; Zinc acetate
  • Indications Hepatolenticular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS
  • Sponsors Alexion AstraZeneca Rare Disease; Wilson Therapeutics

    • Most Recent Events

    • 30 Dec 2023 This trial has been completed in France (Global end date: 30 June 2023).
    • 01 Aug 2023 Status changed from active, no longer recruiting to discontinued as per sponsor decision to terminate the program.
    • 23 May 2023 This trial has been discontinued in Austria and Spain, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top